Complete Androgen Insensitivity Syndrome (CAIS)

A thorough analysis into CAIS using OpenAI Deep Research

Complete Androgen Insensitivity Syndrome (CAIS) is a genetic condition in which a person who is genetically male (46,XY karyotype) is completely unresponsive to androgens (male hormones). As a result, their development follows a predominantly female pattern despite the presence of a Y chromosome and internal testes. Below is an overview of CAIS focusing on development, hormones, health implications, genetics, expert insights, and other medical considerations.

Phenotypical Development

Individuals with CAIS have a female external appearance despite an XY genotype. They are typically raised as girls and often have normal breast development and female body shape at puberty (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). The external genitalia are female-typical – they have a clitoris and labia, with no signs of masculinization (no enlarged clitoris or fused labia) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Pubic and underarm hair is usually sparse or absent, because these secondary hairs depend on androgen stimulation (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

Internally, however, CAIS patients have male gonads (testes) that usually remain undescended (often located in the abdomen or groin) (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf). These testes secrete typical male levels of testosterone, as well as anti-Müllerian hormone (AMH) which causes the regression of female internal organs. Consequently, CAIS individuals lack a uterus and fallopian tubes, and the vagina is often shortened or “blind-ending” (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf). In childhood, CAIS may first be suspected if a girl presents with an inguinal hernia that turns out to contain a testis (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). More commonly, CAIS is recognized in adolescence when a girl fails to begin menstruation (primary amenorrhea) despite normal breast growth (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

These characteristics reflect the fact that without a functioning androgen receptor, the body cannot utilize testosterone or DHT to develop male traits. Lack of androgen receptor (AR) function means the default female development pathway prevails, leading to a feminine phenotype by default (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf) ( Female hyperandrogenism and elite sport - PMC ). In summary, CAIS is not a “mix” of male and female features in the usual sense; rather, it results in a fully feminized appearance externally (female habitus and breasts) with hidden male gonads. The combination of an XY chromosome pattern, testes, and female external anatomy is the hallmark of CAIS.

Hormonal Pathways in CAIS

Under normal circumstances, testosterone can be converted into dihydrotestosterone (DHT) (a potent androgen) or into estradiol (a form of estrogen) via the enzyme aromatase. In CAIS, the testes produce ample testosterone, but the body’s tissues cannot respond to it due to the nonfunctional AR. Instead, much of that testosterone is aromatized into estrogen, which drives female secondary sexual development (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf). This is why girls with CAIS develop breasts and typical female fat distribution at puberty: their high testosterone levels are effectively turned into high estrogen levels, fostering female traits (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf).

Despite having hormone levels (testosterone) in the normal male range, individuals with CAIS do not virilize. The mutated androgen receptor means androgens cannot exert their effects, so male characteristics (such as a penis, male body hair, or deep voice) do not develop (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf) ( Female hyperandrogenism and elite sport - PMC ). Importantly, estrogen actions are intact (estrogen receptors are normal), so female features develop unopposed by androgens.

In terms of clinical management, hormone therapy plays a key role in CAIS, especially after puberty. Many patients with CAIS undergo removal of the undescended testes (see health management section below) to prevent potential cancers. Once the testes (the main source of sex hormones) are removed, estrogen replacement therapy is necessary to maintain feminine secondary characteristics and bone health ( The challenges of androgen insensitivity syndrome - PMC ). Typically, patients are given estrogen medication to mimic the hormones that the testes would have produced via aromatization. Androgen therapy is ineffective in CAIS because the androgen receptor is nonfunctional – giving extra testosterone or DHT would not produce any virilizing effect. Therefore, hormone treatment focuses on providing estrogen (and sometimes progesterone as needed) to support normal female physiology post-gonadectomy ( The challenges of androgen insensitivity syndrome - PMC ). With proper estrogen therapy, individuals with CAIS can maintain healthy feminine characteristics and reduce risks of osteoporosis due to hormone deficiency.

Health Implications: Muscle and Bone

Complete androgen insensitivity has several health implications related to the lack of androgen action:

• Muscle Development and Strength: Androgens are known to promote muscle mass and strength, particularly in males. In CAIS, muscles do not receive androgen signals. Despite this, studies indicate that lean body mass in CAIS patients is similar to that of typical 46,XX females (Body composition and metabolic profile in women with complete androgen insensitivity syndrome - PubMed). These individuals do not gain the greater muscle bulk that 46,XY males normally would, but their muscle development is generally within the female normal range. In fact, one study of women with CAIS found that their fat-free (lean) mass was comparable to female controls, although their body fat percentage was higher than both female and male averages (Body composition and metabolic profile in women with complete androgen insensitivity syndrome - PubMed). Thus, a woman with CAIS may have a slightly higher fat-to-muscle ratio but usually no significant muscle weakness compared to other women. However, lacking any androgen effect (even the small amounts of androgens that typical females have) could mean they might not develop strength quite to the level of an active female who benefits from some androgen activity. Overall, current evidence is reassuring that muscle strength in CAIS is normal for female standards (Body composition and metabolic profile in women with complete androgen insensitivity syndrome - PubMed), but these individuals will not have the increased muscle mass associated with male puberty.

• Bone Density and Fragility: Bone health is a notable concern in CAIS. Androgens contribute to building and maintaining bone density in both men and women, so androgen insensitivity can affect skeletal strength (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). Research shows that bone mineral density (BMD) in women with CAIS who have intact testes is often in the normal female range (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). The estrogen derived from their testes is usually sufficient to develop bones normally, though some patients have shown below-average BMD particularly in the lumbar spine region (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). Once the gonads are removed (eliminating the body’s source of estrogen and testosterone), BMD tends to decrease, especially at the spine and hip (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). Hormone replacement therapy (estrogen) is critical in this scenario: it can improve or maintain bone density, but studies indicate it may not fully normalize bone mass in CAIS patients (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). The reasons are multifactorial – not only the loss of estrogen but also the absence of any AR signaling in bone cells may leave bones slightly less dense even with estrogen treatment (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). While the exact fracture risk in CAIS is not well defined, these findings underscore the importance of monitoring bone health. Doctors will often recommend DEXA scans (bone density tests) and ensure adequate calcium, vitamin D, weight-bearing exercise, and optimal estrogen therapy to protect against osteoporosis in CAIS (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed).

Aside from muscle and bone, overall health in CAIS is generally good with proper management. There is no impact on cognitive development due to CAIS itself, and individuals grow up as girls with typically taller stature than the average 46,XX female (having a Y chromosome can contribute to height) (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf). They may have a tall, slender build. Additionally, because androgens influence certain metabolic functions, research has noted that women with CAIS might have a tendency toward higher LDL cholesterol or slight insulin resistance, suggesting periodic monitoring of cardiovascular risk factors could be prudent (Body composition and metabolic profile in women with complete androgen insensitivity syndrome - PubMed). Maintaining a healthy lifestyle is advised, as for any woman.

Genetic Factors of CAIS

CAIS is rooted in genetics — specifically, in mutations of the androgen receptor (AR) gene. This gene is located on the X chromosome (at locus Xq12) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf) and provides instructions for building the androgen receptor protein, which allows cells to respond to testosterone and DHT. CAIS occurs when a mutation in the AR gene completely knocks out the function of the receptor, so the body cannot use androgens at all.

• Types of Mutations: Scientists have identified hundreds of mutations in the AR gene that can cause androgen insensitivity. In fact, more than 550 different single-nucleotide variants (point mutations) have been documented in AIS cases (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf), and overall reports exceed 800 mutations when including larger genetic changes (Androgen insensitivity syndrome - PubMed). These mutations are scattered throughout the gene, but a large proportion occur in the ligand-binding domain (the part of the receptor that binds testosterone) (Androgen insensitivity syndrome - PubMed). The nature of the mutation often determines the severity of the syndrome:

  • Complete AIS is usually caused by mutations that totally disable the receptor. For example, a mutation introducing a premature stop codon (nonsense mutation) or a frame shift in the DNA code can lead to no functional receptor being made. Certain missense mutations (single amino acid changes) in crucial areas (like the hormone-binding pocket) can also abolish receptor function. These severe mutations lead to CAIS, where there is no response to androgens at all (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

  • Partial or Mild AIS generally results from mutations that allow the AR protein to be made but with reduced function. These could be milder missense changes that only partially impair hormone binding or the receptor’s activity in the nucleus. Such mutations yield some degree of androgen effect, hence the varied phenotypes (PAIS can cause ambiguous genitalia, MAIS causes only slight undermasculinization) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). In other words, the genotype-phenotype correlation shows that the most disruptive AR gene mutations manifest as CAIS, whereas less disruptive ones cause PAIS or MAIS (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). (There are exceptions, and predicting phenotype from genotype is not always straightforward, especially in partial cases.)

• Inheritance Pattern: The AR gene is on the X chromosome, so CAIS is inherited in an X-linked recessive manner (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). A 46,XY individual has only one X chromosome (inherited from their mother). If that X carries a faulty AR gene, the child will have AIS because there is no second copy of the gene to compensate. Typically, the mother is an unaffected carrier of the AR mutation – she has one normal X (which functions correctly, so she is phenotypically normal) and one X with the mutation. When she has children:

  • Each son (46,XY child) has a 50% chance of receiving the mutated X, in which case he will have CAIS (or AIS of some form). If he receives the mother’s normal X, he will be a typical male.

  • Each daughter (46,XX child) has a 50% chance of inheriting the mutated X. A daughter who inherits it will be a carrier like her mother (because her other X from her father is normal, preventing any syndrome). Daughters are not affected by CAIS because the functional AR gene on their other X chromosome ensures normal androgen responsiveness (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

In families with a history of CAIS, we often see this pattern where multiple maternal male relatives may be affected across generations (through carrier females). Interestingly, about 30% of CAIS cases result from a new mutation (de novo) in the AR gene (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). In such instances, the mutation arose in the egg or early embryo, and the mother is not a carrier in her somatic cells. (She might have mosaicism in her ovaries in some cases.) This means CAIS can sometimes occur with no family history. When a spontaneous mutation causes CAIS in one child, the recurrence risk in siblings is low, though not zero if the mother has germline mosaicism (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

Genetic testing can identify mutations in the AR gene to confirm the diagnosis of AIS. In CAIS, a hemizygous mutation in AR (meaning the single X-linked copy in an XY person is mutated) is found in the vast majority of cases (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Testing also allows for carrier detection in female relatives and proper genetic counseling for the family.

Insights from Endocrinologists and Clinical Management

Managing CAIS requires a nuanced and expert approach. Endocrinologists and other specialists who treat CAIS have developed insights and guidelines to ensure the long-term health and well-being of these patients. Key perspectives from medical experts include:

• Multidisciplinary Care: A team approach is essential ( The challenges of androgen insensitivity syndrome - PMC ) (Androgen insensitivity syndrome - PubMed). Because CAIS touches on endocrinology, gynecology, urology, genetics, and psychology, patients are best served by a multidisciplinary team. Experts recommend involving endocrinologists (hormone specialists), surgeons (for gonad removal or potential genital surgery), gynecologists (for vaginal development issues), and psychologists/psychiatrists or counselors. Engagement with patient advocacy/support groups is also encouraged, so the individual and family can learn from others with AIS (Androgen insensitivity syndrome - PubMed).

• Timing of Gonadectomy (Testes Removal): One of the major decisions is if and when to remove the internal testes. Endocrinologists often advise keeping the testes until after puberty is completed (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). This is because the testes will naturally produce estrogen (via testosterone conversion) that allows for full breast development and maturation of the body in puberty (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Removing them too early would force reliance on artificial hormones during puberty. Cancer risk in the testes is relatively low during childhood and the teenage years (comparable to the risk in undescended testes in typical males) and rarely manifests before puberty (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). However, the risk of gonadal tumors (typically testicular germ cell tumors) increases in adulthood – studies estimate the risk may rise to between ~5% and 30% by the third or fourth decade of life (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf) (Androgen insensitivity syndrome - PubMed). Because of this, most experts do recommend prophylactic removal of the testes in early adulthood (often soon after puberty or by the early 20s) to prevent malignancy. Each case is considered individually, weighing the low early risk against the benefits of endogenous puberty. In some modern centers, a delayed gonadectomy with regular monitoring (including ultrasound or MRI and tumor marker checks) is practiced, with surgery by the late teens or early twenties (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). The consensus is that by adulthood, the testes should be removed to eliminate cancer risk, unless the patient strongly prefers otherwise and accepts rigorous surveillance.

• Hormone Replacement Therapy: After gonadectomy, estrogen replacement therapy is mandatory ( The challenges of androgen insensitivity syndrome - PMC ) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Endocrinologists prescribe doses of estrogen to mimic normal ovarian estrogen production. This therapy maintains the female secondary sexual characteristics (breast size, feminine body fat distribution) and is crucial for preventing hypo-estrogenic symptoms (like hot flashes, vaginal dryness) and long-term issues such as osteoporosis ( The challenges of androgen insensitivity syndrome - PMC ). If gonadectomy is done post-puberty, the patient has already developed as a female, and continuing estrogen will preserve those traits. In some cases of partial AIS raised female, a combination of low-dose androgens and estrogens might be used, but in complete AIS, androgens have no effect, so estrogen alone is the focus. Endocrine experts tailor the hormone regimen to maintain appropriate levels similar to a natural female cycle (sometimes using standard female HRT doses or contraceptive pills for convenience). Lifelong compliance with hormone therapy is important for bone health and overall well-being (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed).

• Genital and Sexual Health: Although external genitalia in CAIS are female, the vagina may be shorter than average because it did not fully form in the absence of internal female organs. Vaginal dilation therapy is a commonly recommended, non-surgical approach to lengthen the vagina if needed for comfortable sexual intercourse (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Endocrinologists and gynecologists usually evaluate vaginal depth after puberty. Many patients with CAIS can achieve satisfactory vaginal length through gradual dilation techniques under medical guidance, avoiding the need for surgery. If dilation is insufficient, surgical options exist (such as vaginoplasty using tissue grafts), but these are typically last-resort (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Expert case studies show that with proper technique and patience, dilation is successful in the majority of CAIS patients. Overall, the goal is to ensure the patient can have a normal, pain-free sexual life. This aspect of care is handled with sensitivity and only when the patient is ready.

• Psychological Support and Disclosure: Psychosocial management is considered absolutely critical by experts (Androgen insensitivity syndrome - PubMed). CAIS patients often grow up comfortably as girls, but when they learn that they are chromosomally male and cannot conceive, it can be emotionally challenging. Endocrinologists and psychologists advocate for open, age-appropriate disclosure of the diagnosis, rather than secrecy (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Traditionally, some families withheld the information, which often led to feelings of betrayal or identity crisis if the patient found out accidentally. Modern practice, as noted by specialists, is to gradually educate the individual about her condition during adolescence (often starting in late childhood or early teen years, tailored to maturity level) (Androgen insensitivity syndrome - PubMed). Expert psychological counseling is mandatory to help the patient reconcile the “disconnect” between her chromosomes/gonads and her lived female identity (Androgen insensitivity syndrome - PubMed). With supportive counseling, most individuals with CAIS continue to have a female gender identity and a healthy psychological outcome. They may need support coping with infertility or body image issues (such as lack of menstruation or the presence of internal testes prior to removal). Peer support groups for AIS/DSD can also provide valuable connections. Overall, endocrinologists emphasize that compassionate psychological care and honest communication are key to long-term well-being in CAIS management.

Additional Considerations

Beyond the core medical issues above, there are other important considerations in CAIS:

• Fertility: Individuals with CAIS are infertile. They do not have a uterus or ovaries, so they cannot carry a pregnancy. Additionally, their internal testes do not produce sperm normally (spermatogenesis is impaired in the dysgenetic testes, and the testes are usually removed) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). This means they cannot biologically have children. Some patients pursue alternatives such as adoption if they desire parenthood. It’s important that patients be counseled about this from an appropriate age, as the realization of infertility can be distressing for some.

• Cancer Risk: As noted, there is a risk that the undescended testes in CAIS can develop gonadal tumors (testicular cancer), particularly gonadoblastoma or seminoma, usually in adulthood. Estimates of lifetime risk range widely, with some studies finding around a 3-5% risk by young adulthood and up to 20-30% in later adulthood if the gonads are left in place (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Because of this risk, prophylactic gonadectomy is typically recommended after puberty. If a patient opts to retain her gonads longer, vigilant monitoring (regular exams and imaging) is required. Importantly, removing the gonads carries its own considerations: the patient loses her natural source of hormones and will need lifelong hormone therapy (as discussed) and there is a small risk associated with any surgery. Thus, the timing of gonadectomy is individualized – balancing cancer prevention with developmental benefits. Recent expert surveys indicate some variability in practice, but most clinicians favor removal in the late teens or early twenties (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

• Bone Health: Due to the lack of androgen action (and after gonad removal, lack of endogenous estrogen), bone density can be an issue as described earlier. Patients and doctors must remain proactive about osteoporosis prevention. This includes adhering to estrogen replacement therapy, ensuring adequate nutrition and exercise, and possibly using supplemental calcium/vitamin D. Periodic bone density scans are often advised in adulthood (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed). If any bone loss is detected, adjustments to therapy or additional treatments (like bisphosphonates) might be considered. Fortunately, with proper estrogen therapy, many CAIS women maintain good bone health.

• Psychological Well-Being: Living with CAIS can have psychological impacts, but with support, individuals usually thrive. Gender identity is nearly always female in CAIS, and patients typically have a normal female upbringing, so identity confusion is less common than in partial AIS. The challenges tend to be coping with the knowledge of their XY chromosomes and the inability to menstruate or have children, which can affect self-esteem or sense of womanhood. Professional counseling and support groups are strongly recommended to help process these feelings (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). Encouraging open discussion within a supportive family environment is also important. Many women with CAIS lead very fulfilling lives; some become advocates and connect with others with differences of sex development (DSD), which can be empowering.

• Long-Term Health Monitoring: Other routine health care for CAIS is similar to that for any woman, with a few adjustments. Regular gynecologic care is needed, though Pap smears are not necessary if there is no cervix/uterus. If a vaginoplasty was done or if a vaginal pouch is present, doctors will still monitor vaginal health. General health screenings (breast exams, etc.) are as per female guidelines, noting that breast cancer risk is determined by estrogen exposure (which they have via HRT or aromatized T) and not by their Y chromosome. If the patient is on long-term hormone therapy, periodic blood tests may be done to ensure appropriate hormone levels. Additionally, because AR mutations can rarely have other effects (for example, very mild forms might present just with male infertility), families might be offered genetic counseling to discuss any implications for relatives.

In conclusion, Complete Androgen Insensitivity Syndrome is a condition where an individual’s body cannot use androgens, resulting in a female phenotype despite an XY karyotype. Developmentally, CAIS individuals have female external characteristics (with normal breast development and a shallow vagina) and internal testes. Hormonally, their bodies convert testosterone to estrogen, and they require estrogen therapy after gonad removal, as they cannot respond to androgens. Health-wise, they generally have typical female muscle development but need attention to bone density and have to manage the risk of testicular tumors. Genetically, CAIS is caused by X-linked mutations in the androgen receptor gene and can be inherited or arise spontaneously. Expert care involves a multidisciplinary approach focusing on timing of gonad removal, hormone replacement, vaginal management, and robust psychological support. With appropriate medical care and support, women with CAIS can lead healthy lives. Each patient’s care is personalized, aiming to ensure physical health, psychological well-being, and a positive quality of life (Androgen insensitivity syndrome - PubMed).

Sources:

• Bruce Gottlieb, PhD, & Mark Trifiro, MD. GeneReviews: Androgen Insensitivity Syndrome. University of Washington, Seattle. Updated 2017 (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf).

• StatPearls [Internet]. Androgen Insensitivity Syndrome – NCBI Bookshelf, 2023 (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf) (Androgen Insensitivity Syndrome - StatPearls - NCBI Bookshelf).

• Misakian et al. “Case Report: Low Bone and Normal Lean Mass in Adolescents With CAIS.” Front Endocrinol. 2021 (Case Report: Low Bone and Normal Lean Mass in Adolescents With Complete Androgen Insensitivity Syndrome - PubMed) (Case Report: Low Bone and Normal Lean Mass in Adolescents With Complete Androgen Insensitivity Syndrome - PubMed).

• Bertelloni et al. “Bone Mineral Density in Women with CAIS and Intact or Removed Gonads.” Sex Dev. 2017 (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed) (Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads - PubMed).

• Dati et al. “Body Composition and Metabolic Profile in Women with CAIS.” Sex Dev. 2009 (Body composition and metabolic profile in women with complete androgen insensitivity syndrome - PubMed) (Body composition and metabolic profile in women with complete androgen insensitivity syndrome - PubMed).

• Bohiltea et al. “The challenges of androgen insensitivity syndrome.” Arch Med Sci. 2021 ( The challenges of androgen insensitivity syndrome - PMC ) ( The challenges of androgen insensitivity syndrome - PMC ).

• Hughes IA et al. “Androgen insensitivity syndrome.” Semin Reprod Med. 2012 (Androgen insensitivity syndrome - PubMed) (Androgen insensitivity syndrome - PubMed).

• Zürich A, et al. “Complete androgen insensitivity syndrome: From bench to bed.” Int J Mol Sci. 2020 (MDPI) ( Female hyperandrogenism and elite sport - PMC ) (Androgen Insensitivity Syndrome - GeneReviews® - NCBI Bookshelf). (Plus additional references within).